Levosimendan alone and in combination with valsartan prevents stroke in Dahl salt-sensitive rats  by Levijoki, Jouko et al.
Cardiovascular pharmacology
Levosimendan alone and in combination with valsartan prevents
stroke in Dahl salt-sensitive rats
Jouko Levijoki a, Matti Kivikko a, Piero Pollesello a,n, Jukka Sallinen a,
Minja Hyttilä-Hopponen a, Mikko Kuoppamäki a, Kristiina Haasio a, Olli Gröhn b,
Riitta Miettinen c, Jukka Puoliväli d, Leena Tähtivaara d, Juha Yrjänheikki d,
Antti Haapalinna a
a Critical Care Proprietary Products, Orion Pharma, Orionintie 1, P.O. Box 65, FI-02101 Espoo, Finland
b A.I.Virtanen Institute for Molecular Sciences, Neulaniementie 2, P.O. Box 1627, FIN-70211 Kuopio, Finland
c Tampere University of Technology, Korkeakoulunkatu 10, FI-33720 Tampere, Finland
d Cerebricon Ltd., c/o Charles River Laboratories, Microkatu 1, FI-70210 Kuopio, Finland
a r t i c l e i n f o
Article history:
Received 3 October 2014
Received in revised form
20 January 2015
Accepted 21 January 2015
Available online 29 January 2015
Keywords:
Levosimendan
Stroke
Animal model
Survival
Hypertension
Cerebral blood volume
a b s t r a c t
The effects of levosimendan on cerebrovascular lesions and mortality were investigated in models of
primary and secondary stroke. We aimed to determine whether the effects of levosimendan are
comparable to and/or cumulative with those of valsartan, and to investigate whether levosimendan-
induced vasodilation has a role in its effects on stroke. In a primary stroke Dahl/Rapp rat model,
mortality rates were 70% and 5% for vehicle and levosimendan, respectively. Both stroke incidence (85%
vs. 10%, Po0.001) and stroke-associated behavioral deﬁcits (7-point neuroscore: 4.59 vs. 5.96, Po0.001)
were worse for vehicle compared to levosimendan. In a secondary stroke model in which levosimendan
treatment was started after cerebrovascular incidences were already detected, mean survival times were
15 days with vehicle, 20 days with levosimendan (P¼0.025, vs. vehicle), 22 days with valsartan
(P¼0.001, vs. vehicle), and 31 days with levosimendan plus valsartan (Po0.001, vs. vehicle). The
respective survivals were 0%, 16%, 20% and 59%, and the respective incidences of severe lesions were 50%,
67%, 50% and 11%. In this rat model, levosimendan increased blood volume of the cerebral vessels, with
signiﬁcant effects in the microvessels of the cortex (ΔR¼3.570.15 vs. 2.770.17 ml for vehicle; P¼0.001)
and hemisphere (ΔR¼3.270.23 vs. 2.670.14 ml for vehicle; P¼0.018). Overall, levosimendan signiﬁ-
cantly reduced stroke-induced mortality and morbidity, both alone and with valsartan, with apparent
cumulative effects, an activity in which the vasodilatory effects of levosimendan have a role.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Levosimendan is a cardioprotective inodilator that was developed
for intravenous treatment of acute decompensated heart failure. The
mechanisms of action (Papp et al., 2012) and clinical effects (Nieminen
et al., 2013) of levosimendan have been described previously. In brief,
levosimendan has a cardioprotective inodilatory effect by acting on
three main targets: cardiac troponin C on the contractile apparatus of
cardiomyocytes; ATP-dependent potassium channels on the sarco-
lemma of smooth muscle cells in the vasculature; and mitochondrial
ATP-dependent potassium channels in cardiomyocytes, and potentially
in other key organs (Papp et al., 2012).
In more detail, levosimendan-induced vasodilation has been
described in various models for arteries (Montes et al., 2006;
Ozdem et al., 2006; Usta et al., 2006; Yildiz et al., 2006), veins
(Bragadottir et al., 2013; Höhn et al., 2004; Pataricza et al., 2000),
coronary arteries (Gruhn et al., 1998; Kaheinen et al., 2001; Krassói
et al., 2000; Michaels et al., 2005), and small resistance vessels
(Erdei et al., 2006; Gödény et al., 2013). Very recently, after
experimental cardiac arrest/cardiopulmonary resuscitation in a
rat model, levosimendan was shown to increase cerebral blood
ﬂow, reduce neuronal injury, and improve neurological outcome
(Kelm et al., 2014).
In previous studies with the Dahl/Rapp salt-sensitive rat model,
levosimendan was shown to reduce morbidity and mortality
(Louhelainen et al., 2007), which was ascribed to the correction of
hypertension-induced diastolic heart failure. According to the
literature, however, deaths in the Dahl rat salt-sensitive model
can also be caused by stroke (Yamamoto et al., 2007), and indeed
some stroke-induced mortality studies have been performed in this
rat model (Lin et al., 1999; von Lutterotti et al., 1992). Therefore, a
legitimate question arose as to whether the effects of levosimendan
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on mortality seen in previous studies might have been correlated, at
least in part, to its effects on stroke.
To investigate this further, we set up experimental models in
which the effects of levosimendan were tested in primary and
secondary stroke. In our three-step strategy, we performed three
experimental protocols sequentially: (A) a pilot study aimed both
at testing whether levosimendan has an effect on primary stroke,
and at selecting the correct time for planning a secondary stroke
model (study A); (B) a mortality study in a secondary stroke
model, which was validated by inclusion of a valsartan arm, as
angiotensin receptor blockers are commonly used in secondary
prevention of stroke (study B); and (C) a study in a secondary
stroke model to determine the mechanism of action of the effects
of levosimendan (study C).
Our hypothesis was that levosimendan has positive effects on
stroke. In detail, our aims were: (1) to determine the effects of
levosimendan on stroke-induced death rates in a Dahl/Rapp rat
model of primary and secondary stroke; (2) to determine whether
the effects of levosimendan are comparable to and/or cumulative
with those of valsartan; and (3) to determine whether the
vasodilatory effects of levosimendan have a role in levosimendan
action in this stroke model.
2. Materials and methods
2.1. Animals
The present study was performed in accordance with the
guidelines of the Council of Europe and the US National Research
Council. Approval was granted by the Animal Ethics Committees of
Orion Pharma, or the National Laboratory Animal Centre, Kuopio,
Finland.
Male Dahl salt-sensitive rats (SS/JrHsd; aged 4–6 weeks on
arrival; Harlan US, Indianapolis, USA) were housed at a standard
temperature (2272 1C) and in a light-controlled environment.
The rats had water and food ad libitum. After arrival, the rats were
fed with standard pelleted food for the ﬁrst week. Thereafter, they
were fed with a salt-rich diet (7% NaCl; Special Diet Services, UK)
until the end of the study.
2.2. Levosimendan and valsartan
Levosimendan is the () enantiomer of {[4-(1,4,5,6-tetrahydro-4-
methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono}propanedinitrile, and
it was synthesized by Orion Pharma, Finland. Valsartan [(S)-3-
methyl-2-(N-{[20-(2 H-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl]methyl}
pentanamido)butanoic acid] was purchased from Haorui Pharma-
Chem Inc. (New Jersey, USA). The selected doses of levosimendan and
valsartanwere 1 mg/kg/day and 10 mg/kg/day, respectively. All of the
treatments were administered via the drinking water. The solubility
and stability of levosimendan and valsartan were conﬁrmed prior to
the study. The levosimendan dose was selected on the basis of the
pharmacokinetics and pharmacodynamics data described by
Louhelainen et al. (2007). The consumption of the drinking water
was measured daily. The exposure of the rats to levosimendan and
valsartan was calculated based on the mean drinking water con-
sumption per rat, according to the known drug concentrations in the
drinking water. In addition, the plasma levels of levosimendan of the
rats were determined after 3 weeks and 9 weeks of treatments, using
liquid chromatography–tandem mass spectrometry (as described
previously by Louhelainen et al., 2007). The doses were adjusted
weekly based on the 24-h water consumption and the rat body
weight.
2.3. Study protocols
Three experimental designs were followed, all of which were
based on the Dahl salt-sensitive rat model fed with a high-salt diet,
and which were run sequentially; they are here designated as
studies A, B and C (Fig. 1). For these three experimental protocols,
the rats were randomized to the treatments using random allocation
software, but the investigators were not blinded. The sample size in
study A was determined based on the expected mortality of these
Dahl salt-sensitive rats on a high-salt diet (see Louhelainen et al.,
2007). The sample size in study B was based on the mortality results
from study A. The Animals in Research: Reporting In-Vivo Experi-
ments (ARRIVE) guidelines were followed (Kilkenny et al., 2010).
2.3.1. Study A: primary stroke model
Initially, levosimendan was tested in this primary stroke Dahl/
Rapp rat model (study A), in which the mortality and stroke
incidence were measured, based on the changes in the T2-
weighted magnetic resonance imaging (MRI) and on the histo-
pathology of the rat brains. In this primary stroke model, detection
of the diffusion of ischemic brain lesions and the T2-weighted in-
vivo MRI was performed once a week during treatment weeks 2–8
(see Section 2.7). Seven-point neuroscore testing was performed
once a week during weeks 1–3, and twice a week during weeks
4–8 (see Section 2.5). Brain lesions were also determined post-
mortem after the 8 weeks of the study period (see Section 2.8).
After ex-vivo imaging, the rat brains were processed for histo-
pathological analyses (see Section 2.8). In study A, levosimendan
treatment was started at the same time as salt loading. As no
lesions in the brains were expected at that time, we considered
study A as a primary stroke-prevention model. The results of study
A in terms of time to death and brain lesions were used in the
design and planning of studies B and C. Indeed, when 10% overall
mortality was reached in study A, cerebrovascular lesions were
detectable in the majority of the rats. Thus the levosimendan
treatment in study B began at this later time, and study B was
considered as a secondary stroke model.
2.3.2. Study B: secondary stroke model
The secondary stroke model (study B) was set up and validated
by including valsartan, an angiotensin receptor blocker that is used
as a treatment for secondary prevention of stroke, the use of
which has also shown reduced mortality in similar salt-sensitive
rat models Webb et al., 1998). In this model, the effects of
levosimendan on mortality and stroke incidence were determined
in comparison to and in combination with valsartan. The para-
meters measured included blood pressure, blood volume of
cerebral vessels, cerebrovascular lesions, damage to other organs,
survival time, and survival rate. Here, the effects were studied for
vehicle (n¼20), levosimendan (n¼45), valsartan (n¼46), and
levosimendan plus valsartan (n¼46), on mortality, morbidity,
and histopathological changes (see Section 2.8). The levosimendan
and valsartan treatments were started when 410% mortality was
observed, which was after about 5 weeks on the high-salt diet. The
treatment phase lasted about 5 weeks. Histological analyses of the
brain, heart and kidneys (see Section 2.8) were performed for all of
the rats that survived for at least 3 weeks from the beginning of
these treatments.
2.3.3. Study C: effects on brain blood volume in the secondary stroke
model
A third model was designed to determine the role of
levosimendan-induced vasodilation in mortality for the secondary
stroke model (study C). The overall health status and mortality of
the rats were followed throughout the studies, and non-invasive
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blood pressure was measured at various times. The effects of
levosimendan on other organs were also determined. In study C,
the Dahl salt-sensitive rats were exposed to the high-salt diet
starting at an age of 6–7 weeks, and they continued until the end
of the study, which was up to 9 weeks. Here, the levosimendan
treatment was administered during the last 2 weeks, whereby the
effects of levosimendan (n¼12) on stroke incidence and blood
volume in the small and large cerebral vessels were measured and
compared to the vehicle-treated rats (n¼14).
2.4. Health status and mortality
The overall health status of each rat was monitored every day
by general inspection, when the rat was alive and capable of
drinking and eating. During the levosimendan and valsartan
treatments, in addition to the general inspection, each rat was
handled every working day (i.e., Monday to Friday) to monitor for
changes in their general status. If the condition of the rat was not
normal, the observed abnormalities were recorded and the con-
dition was followed carefully. The body weights of abnormally
behaving rats were measured three times per week. If the general
condition of a rat was clearly less than optimal, and if it appeared
that the rat was not going to survive, it was sacriﬁced using
inhaled carbon dioxide.
2.5. Neuroscore testing
A seven-point neuroscore test was used to assess motor and
behavioral deﬁcits of the rats, as modiﬁed from Zausinger et al.
(2000). The scale was as follows, as the particular rat responses
monitored: normal extension of both forelimbs towards the ﬂoor
when lifted gently by the tail (grade 6); consistent ﬂexion of either
of the forelimbs, which varied from mild wrist ﬂexion and
shoulder adduction to severe posturing with full ﬂexion of wrist
and elbow, and adduction with internal rotation of the shoulder,
when lifted gently by the tail (grade 5); consistently reduced
resistance to a lateral push to either side (grade 3); circling
towards either side if pulled and lifted by the tail (grade 2);
circling towards either side if pulled by the tail (grade 1);
spontaneous circling towards either side (grade 1); and no
spontaneous movements (grade 0). The neurological tests were
conducted by an investigator who was blinded to the treatment
status of the rats.
2.6. Stroke incidence
In the primary and secondary models of studies A and C,
respectively, stroke incidence was assessed using MRI. In the
primary model, MRI analysis was applied at several times, to
follow the development of stroke incidence over time. In the
secondary model, MRI analysis was performed at the end of the
study. The brain lesions were also evaluated by histopathology in
both of the stroke models (studies A and B), to validate the MRI
ﬁndings.
2.7. Magnetic resonance imaging
For the MRI measurements, a Varian Inova console interfaced
to a 4.7 T horizontal magnet was used (Magnex Scientiﬁc Ltd.,
Abington, UK), which was equipped with actively shielded gradi-
ent coils (Magnex Scientiﬁc). For the in-vivo measurements, the
rats were anesthetized with Isoﬂurane (1% in 30/70 O2/N2O), ﬁxed
Study A. Primary stroke model
Control group on normal diet, n = 4
Vehicle on high-salt diet, n = 20
Levosimendan on high-salt diet, n = 20
• Salt diet and treatments at age of 6-7 weeks
• Duration of study: 8 weeks
• MRI once a week, between study weeks 2 to 8 
• Neuroscore testing once a week for study weeks 
1-3, and twice a week for study weeks 4-8
• Blood pressure measurement on weeks 3 and 7
• Histopathology
Study B. Secondary stroke model
Vehicle on high-salt diet, n = 20
Levosimendan on high-salt diet, n = 45
Valsartan on high-salt diet, n = 46
Valsartan+levosimendan on high-salt diet, n = 46
• Daily morbidity and mortality
• Weekly body weight
• Weekly food and water consumption per 24 h
• Blood pressure after 30 days of treatment
• Brain, heart and kidney histologic examinations
at the end of the study
Study C. Secondary stroke model with 
analysis of brain blood volumes
Vehicle on high-salt diet, n = 14
Levosimendan on high-salt diet, n = 12
• Daily morbidity and mortality 
• Weekly body weight 
• Weekly food and water consumption per 24 h
• Blood pressure after 30 days of treatment
Fig. 1. Study outlines. The design of the present study was as a three-step series, in which each successive step was started after the analysis of the previous step, to optimize
the use of resources (both animals and methods) without compromising the power of the statistical analyses needed to conﬁrm or reject our hypotheses. See text for details.
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into a head holder, and positioned in the magnet bore in a
standard orientation relative to gradient coils. An actively
decoupled quadrature volume-surface radio-frequency coil pair
(Rapid Biomedical, Germany) was used for signal transmission and
reception.
2.8. Histopathology
The brain histopathology evaluations were performed for both
of the stroke models. In the secondary model (study B), the
histopathology evaluation was performed also on the heart and
kidneys of all of the rats treated for at least 3 weeks. Transmission
electron microscopy was applied for selected brain samples of the
secondary model, to evaluate the potential stroke-prevention
mechanisms in the brains after the treatments with levosimendan,
valsartan and their combination. At necropsy, the tissues were
removed and ﬁxed in buffered 4% formaldehyde solution (pH 7.2–
7.4) for 2 days, then rinsed three times for 2 h in 0.1 M phosphate
buffer. The brains were immersed in 30% sucrose, and then cut into
50 mm sections and divided into 20 series in cryoprotection
solution containing 30% ethylene glycol and 30% glycerol in
phosphate buffer, and then kept at 20 1C until further processed.
One series of sections was selected for staining. To ensure that
each section had an equal chance of being sampled for the
analysis, the selection of the section series was random, using a
random number table. The brain histopathology was carried out
blinded from the knowledge of the treatment groups. The kidneys
and hearts were processed in parafﬁn, cut into 4 mm sections, and
stained with hematoxylin and eosin, to investigate the general
morphology under light microscopy. All of the ﬁndings were
graded from 0 to 5, where 0 indicated no ﬁndings; 1, minimal
change; 2, slight change; 3, moderate change; 4, marked change;
and 5, severe change.
The brains underwent diaminobenzidine (DAB) staining for
endogenous peroxidase, to monitor for changes in blood circula-
tion. The sections were washed in 0.1 M phosphate buffer, pH 7.4,
for 330 min. They were then incubated in the dark for 20 min in
ﬁltered 0.05% DAB in phosphate buffer. For the color reaction,
100 ml 30% H2O2 was added into 100 ml DAB, and the reaction was
stopped after 8 min. The sections were then washed in phosphate
buffer for 330 min, mounted on gelatine-coated slides, and
studied under light microscopy.
For the general morphology of the brain, Nissl substance, nucleic
acids, and proliferation thionin stain were used. The slides were
dried at 37 1C and treated with chloroform – 99.5% ethanol solution
for 1 h. They were then immersed in 99.5% ethanol for 22 min, in
94% ethanol for 22 min, in 70% ethanol for 2 min, and then in 50%
ethanol for 2 min. After this, the slides were dipped into distilled
water for 1 min. The slides were then stained in ﬁltered thionin
solution for 5 s, rinsed with distilled water, and dehydrated in 50%
ethanol and then 70% ethanol, for 2 min each. The slides were then
dipped into the differentiation solution (70% ethanol and acetic
acid), followed by dehydration in 94% ethanol for 2 min, and 99.5%
ethanol for 22 min, followed by clearance in xylene for 25 min.
Finally the sections were covered with a coverslip and DPX
(distrene, plasticiser, xylene) mounting medium. The heart and
kidney tissues were processed in parafﬁn, cut into 4 mm sections,
and stained with hematoxylin and eosin for their general morphol-
ogy, with examination under light microscopy.
For electron microscopy, selected brains from the secondary
model were post-ﬁxed with phosphate-buffered 1% osmium tetr-
oxide for 2 h. After dehydration with ethanol, embedding in epoxy
resin, thin-sectioning, and post-staining with uranyl acetate and
lead citrate, the thin sections were studied with a JEOL-1200EX
transmission microscope operating at 60 kV (Jeol Ltd., Akishima,
Japan).
2.9. Blood-pressure measurements
Blood-pressure measurements were made using the non-
invasive tail-cuff method (AdInstruments, Oxford, UK). The rats
were habituated to the blood-pressure measurement procedure.
Prior to measuring, a rat was put into a restrainer tube for 10 min,
to allow it to become stabilized under the recording conditions.
The blood pressure was measured in both primary and secondary
models a few times during the studies (Fig. 1).
2.10. Local increase in blood volume by cerebral blood volume
magnetic resonance imaging
Cerebral blood volume (CBV)–MRI was used to investigate local
increases in blood volume of the cerebral small microvessels in
various regions of the brain, including the hemisphere, cortex,
hippocampus, and striatum. For CBV–MRI measurements, the T2
and T2n weighed images were acquired before and after injection
of an intravascular iron-oxide-based contrast agent into the
femoral vein (Endorem; Guerbet SA; 3 mg/kg).
The T2-weighed images were acquired from 10 coronal slices that
covered the cerebrum in an anterior-to-posterior direction, using a
spin-echo sequence with an echo time (ET) of 70 ms, a repetition
time (RT) of 2.5 s, a matrix size of 256128, a ﬁeld of view of
4040 mm2, and a slice thickness of 1 mm. The T2n weighed
images were obtained from the same slices using a gradient echo-
imaging sequence with identical resolution and an ET of 15 ms, a RT
of 1.5 s, and a ﬂip angle of 701. The data were analyzed using in-
house written Matlab software. The ΔR2 (R2¼1/T2) and ΔR2n maps
were calculated from the signal intensity differences between the
pre-contrast and post-contrast agent images. The change in relaxa-
tion rate caused by the intravascular contrast agent was assumed to
be directly proportional to the cerebral blood volume in each pixel.
The ΔR2n is sensitive to both small and large microvessels (diameter,
48 mm), while the ΔR2 changes were dominated by small vessel
contributions (diameter, 8–12 mm).
The ΔR2 and ΔR2n were quantiﬁed from 10 antero-posterior
sections, and from the following four manually selected coronal
regions of interests: right hemisphere, right hippocampus, right
cortex, and right striatum.
2.11. Data management and statistical analysis
Differences between experimental groups were analyzed using
analysis of variance (ANOVA) with post-hoc tests in the case of all
of the normally distributed continuous data. The differences
between the treatment groups for the animal status scores were
compared using the Pearson chi-squared and Fischer's exact tests.
The number of animals used in the studies was justiﬁed by the
need to power the statistical analysis to determine the effects of
the treatments, including the effects on mortality. The cumulative
survival data were deﬁned using Kaplan–Meier analyses across
time and between all of the treatments (IBM SPSS Statistics, v19).
The incidences of histological ﬁndings were analyzed using
Fischer's exact two-tailed tests and Cochran–Armitage tests. All
of the numerical results are shown as means 7S.E.M. For all of the
tests, a P-value (two-sided) of o0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Study A: primary stroke model
In the vehicle salt-diet group, the neuroscores started to decrease
from the second week of the study. Levosimendan reduced and
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markedly postponed stroke-associated behavioral deﬁcits observed
in the neuroscore testing (Fig. 2A). The ﬁrst decline in the neuro-
scores for the levosimendan-treated rats appeared after 6 weeks of
treatment, while in the vehicle-treated rats, the neuroscores started
to decline already after 3 weeks. The control rats on a low-salt diet
had maximum neuroscores throughout the study. Levosimendan
also had beneﬁcial effects on food consumption, body temperature,
and body weight. In the levosimendan group (on the high-salt diet; i.
e., 7% salt content), the body weight gain was similar to that in the
control group (on the low-salt diet; i.e., 0.7% salt content). In the
vehicle group (on the high-salt diet), the body weight gain leveled
off after 4 weeks on the high-salt diet, and then started to decrease
after 6 weeks (data not shown). The ﬁrst deaths in the control high-
salt diet group were observed after 3 weeks (see Fig. 2B). In the
control and levosimendan groups, no deaths were observed before
7 weeks of the study. By the end of the study, the levosimendan
treatment signiﬁcantly reduced the mortality compared to the
vehicle treatment on the high-salt diet (5% vs. 70%, respectively).
No deaths were observed in the control rats maintained on the low-
salt diet.
In the 6th week of the study, more than 50% of the vehicle rats on
the high-salt diet had noticeable T2-weighted MRI changes (Fig. 2C).
No changes were observed at that time for either the control rats
maintained on the low-salt diet or the levosimendan-treated group
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Fig. 2. Study A: effects of levosimendan vs. vehicle in a primary stroke model in Dahl salt-sensitive rats, induced by a high-salt diet. (A) neuroscore; (B) mortality; (C) stroke
incidence and lesion volume; (D) pathological changes in the brain. nnn, Po0.001 (levosimendan vs. vehicle, both for rats on high-salt diet), n, P¼0.022 (rats on control diet
vs. rats on high-salt diet [Vehicle]). (E, F) Representative MRI for detection of brain lesions. Brain T2-weighted MRI images of vehicle-treated (E) and levosimendan-treated
(F) rats. Extensive lesion is seen as a hyperintense area in the MRI image of the vehicle-treated rat (E). The lesion has high signal intensity in T2-weighted images, typical for
high water content (edematous tissue) and destroyed tissue structures. In (C), at week 2 in the levosimendan-treated rats, the MRI shows a bright area (T2w images) right
next to the cerebellum (Dav 2.7 mm2/s), which might have been an erroneous ﬁnding due to an enlarged ventricle, although it was recorded as a minor change.
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(on the high-salt diet). For the ﬁnal MRI measurements at week 8,
there were detectable T2-weighted MRI changes in 85% of the
vehicle-treated rats (e.g., Fig. 2E), compared to only 10% of the
levosimendan-treated rats (e.g., Fig. 2F). The blood pressures of the
levosimendan-treated group (21374 mmHg, in 20 survivors at
week 7) were slightly, but not signiﬁcantly, increased compared to
the vehicle group (21175 mmHg in 8 survivors at week 7).
On the basis of the type and extent of the neuropathological
changes (Fig. 2D), the rat brains could be roughly categorized into
ﬁve different groups: brains with large cavities without brain tissue
(n¼9; all in the vehicle group), brains with moderate to large
necrotic areas (n¼4; three from the vehicle group, one from the
levosimendan group), brains with extensive hemorrhage in the white
matter (n¼6; four from the vehicle group, two from the levosimen-
dan group), and brains with only minor changes (n¼5; one from the
vehicle group, four from the levosimendan group), including, for
example, only one hemorrhage, gliotic patch or infarct. Severe
damage was thus seen for 80% of the brains in the vehicle-treated
rats, while in the levosimendan group, only 15% showed severe
damage; this difference was statistically signiﬁcant (Po0.001).
3.2. Study B: secondary stroke model
3.2.1. Stroke incidence
Based on the histopathology assessments, stroke-induced brain
lesions were seen as large cavities in the brain. In the vehicle
group and in the levosimendan and valsartan treated groups, most
of the rats (460%) had defects, such as pannecrosis (grade 5) in
the brain tissue connected to these cavities (Fig. 3A). However, in
the rats treated with the combined therapy of levosimendan plus
valsartan, only 4 of the rat brains out of 35 (11%) showed
pannecrosis. Instead, there were only smaller necrotic areas, and
the brains were partly restored (grade 2). In connection with the
necrosis, hemorrhages and enlarged ventricles were observed in
the brains of most of the control group rats, but these ﬁndings
were less frequent in the levosimendan or valsartan treated
animals, while less than 10% of the brains in the rats treated with
both levosimendan and valsartan had enlarged ventricles (3%) or
hemorrhages (6%).
Electron microscopy evaluation of the brain cortex revealed more
vesicle formation and uneven, thinner basal lamina in the vessels
after the levosimendan or valsartan treatments than after the
levosimendan plus valsartan combination treatment (Fig. 3B). As
veriﬁed by the DAB staining, levosimendan prevented blood occlu-
sion formation (i.e., occlusion seen for 0/7 animals) in the brains of
the rats that survived until the end of study B. In contrast, in the
brains of both the valsartan and the levosimendan plus valsartan
combination groups, occlusion formation was seen (5/9, 10/27,
respectively; P¼0.029, P¼0.037 compared to the levosimendan
group, respectively; Fig. 3C). No differences were observed in
bleeding or gliosis between the levosimendan, valsartan and combi-
nation groups (7/7, 8/9, 15/27, respectively). For the white matter
destruction (as visualized by hematoxylin and eosin staining), in the
high-salt diet control group, all of the brains of the rats studied had
white matter lesions (i.e., 100%). Instead, this was seen as 71% and
75% of the brains of the levosimendan and valsartan treated rats,
respectively, which compared to only 31% in the levosimendan plus
valsartan combination group. The stroke incidence in the levosimen-
dan plus valsartan combination treatment thus declined in terms of
the pan-necrosis/necrosis and white matter lesions in the brains.
3.2.2. Mortality
In the levosimendan plus valsartan combination treatment
group, there was also lower mortality compared to the other
groups (Fig. 3D). The mean survivals were 15, 20, 22, and 31 days
in the control, levosimendan, valsartan, and combination treat-
ment groups, respectively. The respective mortalities were 100%,
84%, 80%, and 41%.
3.2.3. Blood pressure
After 4 weeks of these treatments, there were no effects on
blood pressure with valsartan alone (21176 mmHg) or in combi-
nation with levosimendan (217714 mmHg). In the levosimendan
and valsartan combination treatment group, the blood pressure
was maintained high to the end of the study (21477 mmHg).
There was no correlation between the severity of the brain lesions
and the blood pressure.
3.2.4. Histopathology of heart and kidneys
In the histopathological analysis of the heart, all of the treatment
groups showed medial thickening of coronary arteries and myocar-
dial necrosis or necrotic foci. The inter-group differences were only
minor (data not shown). In the histopathological analysis of the
kidneys, all of the treatment groups showed inﬂammatory cell
inﬁltrates, tubular hyaline deposits, and basophilic foci with thick-
ened basement membrane, although the severity was lower in the
levosimendan and valsartan combination treatment group, without
reaching signiﬁcance (data not shown).
3.3. Study C: effects on brain blood volume in the secondary stroke
model
In this study, in the vehicle-treated and levosimendan-treated
rats, the incidence of brain lesions was 85% and 36%, respectively
(Fig. 4A). CBV–MRI was used to study local increases in the blood
volumes. Here, compared with the vehicle treatment, there was a
tendency for levosimendan to increase the blood volume of
cerebral small microvessels in various regions of the brain,
including the hemisphere, cortex, hippocampus, and striatum
(Fig. 4B). In some of the regions, these effects reached signiﬁcance
(hemisphere, P¼0.018; cortex, P¼0.001). The tendency of levosi-
mendan to increase the blood volume in the cerebral large vessels
was, however, less marked (Fig. 4C). Interestingly, levosimendan
did not alter the systolic (Fig. 4D) and diastolic blood pressures.
4. Discussion
We set up three experimental protocols here to answer the
following questions: (1) ‘Does levosimendan prevent stroke in a
primary prevention model?’; (2) ‘Does levosimendan prevent sec-
ondary stroke?’; (3) ‘Does levosimendan act in a comparable and
cumulative way to valsartan?’; and (4) ‘What role does vasodilation
promoted by levosimendan have in stroke prevention?’.
Study A here was a primary stroke prevention model, as the
study drugs were started before any brain lesions had occurred. To
the best of our knowledge, there is no widely accepted model for
secondary stroke prevention, as to mimic secondary stroke pre-
vention the experimental drug treatment should be started only
after brain lesions are expected to have already occurred. Based on
the data from study A, we were able to conclude that once an
overall death rate of 10% had been reached, the majority of the rats
had detectable brain lesions. This led us to start the drug treat-
ments only after this point in studies B and C, to represent the
effects of the experimental drugs on secondary stroke prevention.
To validate the model, we used the positive control in study B of
valsartan, which is an angiotensin receptor blocker that has been
widely used in secondary prevention of stroke. In study B, the test
drug was thus levosimendan, which was administered both alone
and in combination with valsartan. Finally, the third study (study
C) was performed on the secondary stroke prevention model, to
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determine what the role of levosimendan-induced vasodilation
might be in terms of the overall effects of levosimendan.
Our main ﬁndings are that in both of these primary and secondary
prevention models in Dahl salt-sensitive rats, levosimendan improves
survival and prevents strokes. The beneﬁcial effects of levosimendan
and valsartan were similar in the secondary stroke prevention model,
and a supra-additive improvement in survival was seen when
levosimendan and valsartan were combined.
The survival improvements were mainly related to the preven-
tion of strokes, as can be seen from the MRI and brain histopathol-
ogy ﬁndings. The animals that died in the course of this study
showed only minor pathologies for the heart and kidneys. The MRI
data were in very good agreement with the brain histology results.
Indeed, at the end of the primary stroke model study, 85% of the
vehicle-treated rats showed histologically severe brain lesions, and
at the same time, MRI changes were observed in 85% of these rats.
The beneﬁts of levosimendan combined with valsartan were
not only limited to lower mortality and lower stroke incidence.
These rats that were treated with the levosimendan and valsartan
combination were also healthier, as shown by their higher neuro-
scores and normal body weight gain and water intake.
Our results indicate that the positive effects of levosimendan
on survival appear not to be dependent on decreased blood
pressure. However, we observed an increase in blood volume in
the brain microvessels with levosimendan treatment. We can
therefore speculate that the mechanisms underlying the beneﬁcial
effects of levosimendan in these models are related to its local
vasodilatory properties. This hypothesis is also supported by very
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recent data that show that levosimendan increases cerebral blood
ﬂow, reduces neuronal injury, and improves neurological outcome
after experimental cardiac arrest/cardiopulmonary resuscitation in
a rat model (Kelm et al., 2014).
On the other hand, other pharmacologic effects of levosimen-
dan have been described that might also be beneﬁcial, such as
anti-ischemic properties (Du Toit et al., 2008; Grossini et al., 2005;
Kersten et al., 2000; Leprán et al., 2006; Levijoki et al., 2001; Papp
et al., 2006), improved endothelial function (Parissis et al., 2008),
and anti-aggregatory effects on platelets Ambrus et al., 2012; Bent
and Plaschke, 2013; Kaptan et al., 2008; Plaschke et al., 2012).
Therefore, the local vasodilation induced by levosimendan might
only partially account for the reduction in the incidence of stroke.
Previous nonclinical studies have shown some effects of levo-
simendan on the brain (Hein et al., 2013; Roehl et al., 2012).
Moreover, a recent report showed that levosimendan was bene-
ﬁcial in a model of injury to the immature brain following
cardiopulmonary bypass (Namachivayam et al., 2014). Finally,
Varvarousi et al. (2014) described positive effects of levosimendan
in post-cardiac arrest brain injury, and Bleilevens et al. (2014)
showed that levosimendan treatment signiﬁcantly reduces cere-
bral infarct size in the cortex in a rat model.
Consideration should be given to the effects of these treat-
ments on systemic blood pressure. Neither levosimendan nor
valsartan showed any signiﬁcant effects on blood pressure in our
model. One explanation might be that the salt-loading in this rat
population that is prone to extremely high blood pressures can
lead to treatment-resistant hypertension. Another explanation
might be that the rats that survived in the active treatment groups
actually had lower blood pressures compared to the controls that
also received high-salt loading, such that the salt-loaded rats died
prematurely, and hence their eventual higher blood pressures
could not be detected.
5. Conclusions
The present study shows that levosimendan can reduce stroke-
induced mortality and morbidity, both when used alone and when
combined with valsartan, with apparent cumulative effects. These
positive effects of levosimendan were seen both in the primary
(study A) and secondary (studies B and C) stroke models. As
levosimendan is approved for human use and as the levosimendan
doses investigated here for stroke prevention are similar to that
approved for treatment of acute heart failure, there is a strong
rationale to plan exploratory clinical trials in human to assess the
safety and efﬁcacy of levosimendan for prevention of secondary
stroke.
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